Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2012Stem Cells Translational MedicineOpen Access

Functional Impairment of Human Resident Cardiac Stem Cells by the Cardiotoxic Antineoplastic Agent Trastuzumab

View Full Paper
Ask AI
Bookmark
Share

Key result

Trastuzumab abrogates hCDC functional benefits in infarcted mouse hearts, worsening ejection fraction and scar thickness.

  • n=24

Why the study?

Trastuzumab cardiotoxicity may involve inhibition of human adult cardiac-derived stem cells in addition to direct adverse effects on cardiomyocytes.

Does Trastuzumab impair the regenerative function of human resident cardiac stem cells?

Population

Human cardiosphere-derived cells in vitro and acutely infarcted mouse hearts (n=12 per group)

Comparison

Trastuzumab-treated cells or mice vs untreated cells or hCDCs alone

Design

Preclinical in vitro and in vivo study

Authors

ABAndreas S. BarthJohns Hopkins UniversityYZYiqiang ZhangHeilongjiang University of Chinese MedicineTLTao‐Sheng LiNagasaki University

Discussion

Loading...

Member takes

Implication

TZM may impair cardiac stem cell function; leaves open contribution to clinical cardiotoxicity.

Structured PICO

Does Trastuzumab impair the regenerative function of human resident cardiac stem cells?

P
Population
In vitro and in vivo study evaluating the effects of Trastuzumab on human cardiosphere-derived cells in acutely infarcted mouse hearts (n=12 per group).
I
Intervention
Trastuzumab (TZM)
C
Comparator
Untreated cells (in vitro) or hCDCs alone (in vivo)
O
Outcome
Cardiogenic differentiation and microvascular network formation (in vitro); ejection fraction, infarct scar thickness, and capillary density (in vivo)surrogate

Trastuzumab impairs the cardiomyogenic and angiogenic capacities of human resident cardiac stem cells, providing a potential novel mechanism for its cardiotoxicity.

Cite This Study

Barth et al. (2012) studied Cardiotoxicity (n=24). Trastuzumab vs. hCDCs alone was evaluated on Ejection fraction, infarct scar thickness, and capillary density. Trastuzumab abrogated the functional benefits of human cardiosphere-derived cells in acutely infarcted mouse hearts (n=12 per group), resulting in lower ejection fraction and thinner infarct scar.

synapsesocial.com/papers/6aabce34083100ccc151f814https://doi.org/10.5966/sctm.2011-0016
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience2002 · 1,513 citations
  2. 2Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy2002 · 476 citations
  3. 3Neuregulins Promote Survival and Growth of Cardiac Myocytes1998 · 505 citations
  4. 4Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience2006 · 367 citations
  5. 5Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy Specimens2007 · 1,145 citations